AI in Pathology Market Achieve USD 119 Billion Milestone by 2033

Trishita Deb
Trishita Deb

Updated · Mar 27, 2024


At Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
Advertiser Disclosure

At Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.


The global AI in Pathology market is poised for substantial growth, anticipated to escalate from USD 27.2 billion in 2023 to an estimated USD 119 billion by 2033. This remarkable expansion, forecasted at a Compound Annual Growth Rate (CAGR) of 15.9% during the period from 2024 to 2033, underscores the burgeoning role of artificial intelligence in transforming pathology practices. The sector’s evolution is notably propelled by the integration of AI to enhance diagnostic accuracy, improve treatment planning, and optimize healthcare resources through advanced data analysis and image processing capabilities. AI models are increasingly employed to analyze clinical, genomic, and pathology image data, facilitating personalized medicine and efficient healthcare service delivery.

One of the significant growth drivers within this market is the drug discovery segment, which, due to advancements in imaging technologies and increased R&D expenditures, has emerged as a dominant force. The pharmaceutical and biotechnology companies, as end-users, are expected to witness the fastest growth, leveraging AI in pathology for drug development and toxicology testing. North America, in particular, is projected to exhibit the highest growth rate, attributed to substantial investments in modernizing pathology infrastructure and a surge in digital pathology solution adoption.

However, the journey of AI in pathology is not without its challenges. The high cost of digital pathology systems, a scarcity of skilled AI professionals, and ambiguous regulatory guidelines pose significant barriers. Despite these hurdles, the recent approval of over 500 healthcare AI algorithms by the FDA, with a notable concentration in medical imaging, signals a robust regulatory endorsement of AI’s potential in healthcare. These developments, alongside an increased focus on leveraging AI for non-clinical applications like population health and revenue cycle management, paint a promising picture of AI’s role in redefining pathology and healthcare at large​​​​.

Key Takeaways

  • In 2023, the AI in Pathology market was valued at USD 27.2 Billion, projected to reach USD 119 Billion by 2033, growing at a 15.9% CAGR.
  • The software segment led the market in 2023, holding a significant share of 74.5%, highlighting the growing reliance on AI software in pathology workflows.
  • Dominating the neural network analysis, the Conventional Neural Network segment captured 45.2% of the market in 2023, showcasing its pivotal role in improving pathologists’ efficiency.
  • The Drug Discovery application segment claimed a notable market share of 46.7%, reflecting AI’s crucial role in advancing personalized medicine through new drug development.
  • Hospitals and Reference Laboratories were the predominant end users in 2023, with a 58.4% market share, indicating a surge in demand for AI solutions to manage growing pathology caseloads.
  • With a 31.4% market share, the Asia-Pacific region led the global AI in Pathology market in 2023, driven by rapid adoption of AI technologies in countries like India and China.
  • From 2017 to 2020, more than 10,394 pathology specimens were tested remotely in Jianghua Country, highlighting a trend towards digital pathology with an annual increase of over 10%.
  • The estimated number of new cancer cases was 14.1 million in 2012, with projections indicating a rise to over 20 million annually by 2030, underscoring the urgent need for advanced diagnostic solutions.
  • The cost for a typical pathology system ranges between USD 500,000 to USD 1,500,000, pointing to significant investment requirements for adopting digital pathology infrastructure.
AI In Pathology Market Growth
To learn more about this report – request a sample report PDF

AI in Pathology Statistics

  • Diagnostic Speed and Accuracy: Initial studies show that pathologists, with AI’s aid, can diagnose faster and more accurately. In a breast cancer study involving 70 patients, sensitivity for detecting micrometastases improved from 83.3% to 91.2% with AI assistance.
  • Digital Pathology Adoption: The transition to digital pathology is gradual, with only a few pathology laboratories having established a fully digital workflow as of the early 2020s.
  • AI Model Performance: The best-performing AI model in a study achieved a diagnostic accuracy with an AUROC (Area Under the Receiver Operating Characteristic curve) of 0.960, surpassing the performance of 11 pathologists under time pressure.
  • Cost Savings: Digital pathology, potentially enhanced by AI, could save a university center an estimated USD 12.4 million over five years, attributed partly to improved diagnostic accuracy.
  • Data Requirements for AI: The accuracy of AI algorithms is highly correlated with the volume of data used for training. In one study, the validation error decreased by approximately a factor of 10 when the data set was increased 100 times.
  • Accuracy improvements with AI: Studies show AI can enhance diagnostic accuracy in pathology by up to 85% when used in conjunction with human pathologists, reducing error rates significantly.
  • Time saved by AI in diagnosis: AI has the potential to reduce the time required for diagnosing diseases from whole-slide images by over 50%, making the diagnostic process more efficient.
  • Study on Multimodal Data Integration: Researchers used 5,720 patient data, including 6,592 whole slide images and molecular data, to predict patient outcomes, outperforming traditional models in 12 of 14 cancer types.
  • First FDA-cleared AI Product in Digital Pathology: Paige Prostate, an AI tool for detecting prostate cancer in digital slides, received FDA clearance, improving cancer detection by 7.3% on average in a clinical study.
  • Cost Reduction in Drug Development: Artificial intelligence can decrease preclinical development costs by 20% to 40% across U.S. laboratories, addressing the financial challenge of drug development.

Emerging Trends

Emerging trends in artificial intelligence (AI) in pathology are revolutionizing the way diseases are diagnosed and treated. Digital pathology, leveraging AI, is enhancing the analysis of histological features and fostering the development of molecular pathology. This transformation is characterized by a few key trends:

  • Digital and Molecular Pathology Integration: The integration of digital pathology with molecular pathology is providing a comprehensive approach to disease diagnostics. Molecular pathology, by offering spatially resolved molecular information, complements the structural data from traditional histopathology. This multidimensional data poses significant challenges for data processing, mining, and analysis, necessitating advanced AI algorithms to interpret the complex information​​.
  • AI-Enabled Digital Pathology Algorithms for Companion Diagnostics: Collaborations between AI pathology firms and biopharma companies, such as PathAI and Roche Tissue Diagnostics, are focusing on developing AI-enabled digital pathology algorithms. These efforts target the needs of immuno-oncology and antibody drug conjugate development, aiming to precisely select patients for treatment. AI-powered assays developed through these partnerships are expected to be commercialized, enhancing diagnostic capabilities globally​​.
  • Advances in Digital Imaging and Histopathology: With the advent of digital imaging techniques, pathology has seen significant improvements in diagnosing diseases. Digital imaging allows for detailed visualization of tissue specimens, facilitating faster and more accurate diagnoses. Additionally, the role of histopathology remains critical, with molecular pathology and the construction of tissue microarrays emerging as vital tools for disease detection and research​​.
  • Precision Medicine and Biotechnology: The field of pathology is pivotal to the shift towards precision medicine, where treatments are increasingly being tailored to the individual’s genetic makeup. Pathology biotechnology is crucial in identifying disease-causing mutations and developing targeted therapies. This trend is supported by advances in molecular taxonomy and dedicated tissue banks, which are enhancing the diagnosis and treatment of diseases​​.
  • Digitalization and Standardization in Pathology: The digitalization of pathology is improving accuracy, efficiency, and cost-effectiveness. However, it also brings challenges such as the need for standardized terminology and data sharing. Digital workflows, from electronic microscopes to cloud-based systems, are streamlining pathology processes, enabling better disease diagnosis and treatment​​.

Use Cases

Artificial Intelligence (AI) is transforming the field of pathology, enhancing diagnostic accuracy, efficiency, and uncovering new scientific insights. The integration of AI into pathology workflows addresses key challenges and opens up new opportunities for advancements in medical research and patient care. Below are the primary use cases of AI in pathology, highlighting the significant impact AI is making in this domain:

  • Enhanced Diagnostic Precision and Speed: AI’s ability to examine vast amounts of data, such as thousands of pathology slides or genomic information, brings a new level of precision and speed to pathology. For instance, AI models have demonstrated over 96% accuracy in analyzing prostate cancer biopsy slides, matching the expertise of seasoned pathologists. This demonstrates AI’s potential to democratize access to high-level diagnostic capabilities​​.
  • Productivity and Efficiency in Pathology Workflows: AI significantly boosts pathologists’ productivity by automating time-intensive manual analysis, such as cell counting or tumor size measurement, and streamlining workflows. An example of this impact is at Hospital Campus de la Salud in Spain, where Philips’ AI digital pathology implementation increased pathologist productivity by 21%, enabling the analysis of over 280,000 samples per year by 23 pathologists​​.
  • Advancements in Scientific Research: AI facilitates groundbreaking research by enabling early detection of disease markers and predicting treatment responses, which were previously unachievable. For example, AI algorithms have identified 28 new types of brain cells by analyzing thousands of pathology slides, showcasing the potential for AI to revolutionize clinical decision-making and research​​.
  • Comprehensive Cancer Diagnosis and Treatment: AI models, such as those developed by the Computational Pathology Group at Radboud University Medical Center, utilize deep learning techniques for cancer and tumor detection, significantly speeding up diagnosis and aiding in the development of efficient cancer treatment plans​​.
  • Tackling Pandemics: AI has played a crucial role in fighting and preventing pandemics by speeding up vaccination research, diagnosing diseases, and predicting global outbreaks. For instance, AI-based tools have been developed for rapid COVID-19 detection, demonstrating AI’s capability to enhance public health response during pandemics​​.
  • Pathology Education and Training: AI assists in pathology education by providing pathologists with insights into tissue sample analysis and aiding in the detection of anomalies that might be overlooked by human observers. This enhances the learning experience and prepares pathologists for more accurate diagnoses​​.
  • Accelerating Drug Development: AI can drastically reduce the time and cost associated with drug development by analyzing genomic, health records, and molecular data to predict drug interactions and treatment outcomes. For example, the University of Sheffield and AstraZeneca developed the AI model DrugBAN, which can significantly shorten the drug discovery process​​.

Key Players Analysis

The AI in Pathology market is experiencing a significant transformation, driven by the integration of artificial intelligence (AI) technologies that enhance diagnostic accuracy, improve workflow efficiencies, and enable more personalized patient care. Among the forefront of this evolution are several key players, each contributing unique innovations and strategic advancements to the field.

Aiforia Technologies is distinguished by its cloud-based platform, offering AI-powered image analysis to assist pathologists in making more accurate and faster diagnoses. This approach not only democratizes access to advanced diagnostic tools across various regions but also supports the scalability of pathology services to meet growing demands.

Ibex Medical Analytics stands out for its pioneering work in developing AI-based cancer diagnostics solutions. Its precision and reliability in identifying cancerous cells in tissue samples represent a critical step forward in oncology, offering hope for earlier and more accurate cancer detection.

PROSCIA is another notable contributor, emphasizing the digital transformation of pathology through its AI-powered software. This platform enhances the efficiency of pathology practices by streamlining workflows and facilitating the management of large digital datasets, thus enabling faster and more informed clinical decisions.

Roche Tissue Diagnostics integrates AI into its comprehensive suite of tools and technologies, focusing on improving cancer diagnostics. Their contributions are pivotal in advancing precision medicine, offering pathologists and researchers innovative solutions that aid in the detection and characterization of various cancer types.

Visiopharm is recognized for its AI-driven image analysis software, which plays a crucial role in both research and diagnostic settings. By offering quantitative pathology and biomarker assessment, Visiopharm aids in the development of new therapies and the improvement of patient outcomes.

Deep Bio specializes in AI solutions for prostate cancer diagnosis, providing a platform that significantly enhances the accuracy and efficiency of detecting and grading cancer in biopsy samples. This focus on a specific cancer type demonstrates the potential of AI to specialize and improve outcomes in particular domains of pathology.

Mindpeak offers AI tools designed to reduce the workload of pathologists by automating the analysis of cancer cells in tissue samples. Their solutions improve the speed and precision of diagnoses, contributing to the overall efficiency of the diagnostic process.

Hologic is leveraging AI in enhancing diagnostics in women’s health, particularly in the areas of breast and cervical cancer. Their innovative technologies improve the accuracy of screenings and diagnostics, playing a crucial role in early detection strategies.

Aiosyn stands out for its AI-driven analytics that enhance pathology workflows and diagnostic accuracy. By integrating AI into routine pathology practice, Aiosyn aids in the rapid and reliable diagnosis of diseases, facilitating better patient management.

Lumea is another innovative company, revolutionizing the field with its digital pathology solutions. By combining AI with cutting-edge imaging technology, Lumea strives to improve the accuracy and efficiency of pathology diagnostics, thereby enhancing patient care.

Other key players in the market also contribute significantly to the AI in Pathology landscape, each bringing their own innovations and expertise. These companies play a crucial role in the continuous development of AI applications in pathology, driving the market forward through their commitment to improving diagnostic methods and patient outcomes.

Recent Developments

  • In November 2023, Leica Biosystems forging partnerships with global hospitals and laboratories to adopt cutting-edge digital pathology workflows. This collaboration features Leica choosing Paige to equip Aperio GT 450 scanners with advanced AI-driven image handling software.
  • In August 2023 marked a milestone for Roche Tissue Diagnostics as their VENTANA PD-L1 (SP142) Assay received FDA approval. This advancement, facilitating pembrolizumab therapy, illustrates AI’s growing influence in pathology diagnostics.
  • In April 2023, a partnership was established between Indica Labs Inc. (US) and Lunit Inc. (South Korea) to create a seamless integration between Lunit’s AI pathology solutions and Indica Labs’ HALO AP software, enhancing image management capabilities.
  • In March 2022, Ibex Medical Analytics and Dedalus Group announced a collaborative effort to merge Ibex’s AI pathology tools with Dedalus’s digital platforms, aiming to streamline pathologist workflows and extend AI tool accessibility.


The AI in Pathology market is undergoing rapid transformation, poised for significant growth and innovation. The integration of artificial intelligence is revolutionizing pathology by enhancing diagnostic accuracy, speeding up disease detection, and facilitating personalized medicine. Despite facing challenges such as high system costs and regulatory complexities, advancements in AI technology and supportive regulatory endorsements signal a positive outlook.

Key market players are continuously innovating, focusing on partnerships and technological advancements to meet the growing demands for efficient and accurate diagnostic solutions. The future of pathology is closely tied to AI, with potential to improve patient outcomes, streamline workflows, and reduce healthcare costs. As AI technologies evolve, their integration into pathology practices is expected to become more widespread, marking a new era in healthcare diagnostics and treatment planning.

Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.